Armata Pharmaceuticals Announces Structural Biology Publication
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2024
0mins
Source: PRnewswire
Phage Structure Research: Armata Pharmaceuticals announced a publication detailing the structure of phage Pa193, which is part of their multi-phage clinical candidate aimed at treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients.
Advancements in Phage Therapy: The study enhances understanding of phage biology and structural components, potentially expanding the use of phages as therapeutics for various dangerous pathogens beyond P. aeruginosa.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
